Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BETA Technologies, Inc.BETA · Entity 1930 | Director | June 11, 2026 | June 12, 2026 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director · Chairperson & CEO | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BETA Technologies, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,213 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213 |
UNITED THERAPEUTICS Corp
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,943 |
Reported balance
After 2026-10-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,304 |
Reported balance
After 2026-10-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 330,964 |
Reported balance
After 2026-10-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 329,472 |
Reported balance
After 2026-10-13 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 327,965 |
Reported balance
After 2026-10-13 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 326,513 |
Reported balance
After 2026-10-13 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,883 |
Reported balance
After 2026-10-13 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,185 |
Reported balance
After 2026-10-13 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,683 |
Reported balance
After 2026-10-13 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,523 |
Reported balance
After 2026-10-13 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,443 |
Reported balance
After 2026-10-13 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 249,108 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 45,596 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,902 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15 | Indirectby Trust | 242,910 |
Reported balance
After 2026-10-13 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Direct | 40,513 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 40,513 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 166 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 166 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2023 Filed Feb 26, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 32,499 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001106578-26-000001 · primarydocument.xml · derivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,499 Underlying: Common Stock · 32,499 shares Expires not disclosed F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 207,720 | $0.00 Strike: $217.50 | $0.00 |
DisclosureSEC source: 0001106578-26-000001 · primarydocument.xml · derivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,720 Underlying: Common Stock · 207,720 shares Expires 2033-03-15 F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 8,000 | $0.00 Strike: $113.08 | $0.00 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · derivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,000 Underlying: Common Stock · 8,000 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 343 | $225.67 | $77,403.23 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F8 · price: This transaction was executed in multiple trades at prices ranging from $225.33 to $225.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,092 | $224.84 | $245,522.77 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F7 · price: This transaction was executed in multiple trades at prices ranging from $224.33 to $225.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,587 | $223.61 | $354,874.31 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F6 · price: This transaction was executed in multiple trades at prices ranging from $223.24 to $224.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 402 | $222.63 | $89,498.10 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,152 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $222.24 to $223.155. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 809 | $221.43 | $179,132.83 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,554 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $221.21 to $222.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,642 | $220.55 | $582,694.16 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,363 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $220.025 to $220.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,125 | $219.79 | $247,264.54 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $219.02 to $219.975. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,000 | $113.08 | $904,640.00 |
DisclosureSEC source: 0001415889-23-005018 · form4-03162023_040306.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 8,000 | $0.00 Strike: $113.08 | $0.00 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · derivative · entry 21 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 8,000 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 246 | $232.78 | $57,263.83 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F15 · price: This transaction was executed in multiple trades at prices ranging from $232.53 to $233.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 446 | $231.81 | $103,387.44 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F14 · price: This transaction was executed in multiple trades at prices ranging from $231.52 to $232.265. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 426 | $230.71 | $98,284.16 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F13 · price: This transaction was executed in multiple trades at prices ranging from $230.355 to $231.105. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,479 | $229.80 | $339,874.35 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F12 · price: This transaction was executed in multiple trades at prices ranging from $229.325 to $230.285. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 302 | $228.88 | $69,121.67 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,727 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F11 · price: This transaction was executed in multiple trades at prices ranging from $228.32 to $229.245. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 158 | $227.54 | $35,951.35 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,029 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F10 · price: This transaction was executed in multiple trades at prices ranging from $227.25 to $227.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 755 | $226.52 | $171,022.37 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $226.065 to $227.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,395 | $225.46 | $314,516.56 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,942 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F8 · price: This transaction was executed in multiple trades at prices ranging from $225.065 to $226.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,793 | $224.55 | $627,179.32 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,337 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F7 · price: This transaction was executed in multiple trades at prices ranging from $224.03 to $225.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,000 | $113.08 | $904,640.00 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 8,000 | $0.00 Strike: $113.08 | $0.00 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · derivative · entry 20 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 8,000 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 344 | $230.63 | $79,337.51 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F6 · price: This transaction was executed in multiple trades at prices ranging from $230.54 to $230.725. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,863 | $230.01 | $428,512.73 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $229.52 to $230.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,126 | $228.85 | $486,536.80 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $228.515 to $229.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,264 | $228.08 | $516,374.70 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,463 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $227.45 to $228.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,350 | $226.80 | $306,182.43 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,727 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $226.365 to $227.295. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 53 | $225.29 | $11,940.37 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,077 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,000 | $113.08 | $904,640.00 |
DisclosureSEC source: 0001415889-23-004837 · form4-03142023_040301.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 8,000 | $0.00 Strike: $113.08 | $0.00 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · derivative · entry 25 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,000 Underlying: Common Stock · 8,000 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 382 | $225.24 | $86,042.98 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 21 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F19 · price: This transaction was executed in multiple trades at prices ranging from $225.05 to $225.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,460 | $224.31 | $327,487.20 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 20 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F18 · price: This transaction was executed in multiple trades at prices ranging from $223.955 to $224.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,092 | $223.55 | $467,664.51 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 19 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,972 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F17 · price: This transaction was executed in multiple trades at prices ranging from $222.92 to $223.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,501 | $222.42 | $333,850.62 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 18 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,064 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F16 · price: This transaction was executed in multiple trades at prices ranging from $221.91 to $222.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,302 | $221.39 | $288,255.64 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,565 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F15 · price: This transaction was executed in multiple trades at prices ranging from $220.86 to $221.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 910 | $220.20 | $200,385.00 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,867 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F14 · price: This transaction was executed in multiple trades at prices ranging from $219.755 to $220.625. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 353 | $219.19 | $77,375.66 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,777 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F13 · price: This transaction was executed in multiple trades at prices ranging from $218.62 to $219.525. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,000 | $113.08 | $904,640.00 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 8,000 | $0.00 Strike: $113.08 | $0.00 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · derivative · entry 24 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,000 Underlying: Common Stock · 8,000 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 57 | $235.99 | $13,451.43 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 190 | $233.23 | $44,314.63 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F12 · price: This transaction was executed in multiple trades at prices ranging from $233.015 to $233.855. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 318 | $232.49 | $73,930.58 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F11 · price: This transaction was executed in multiple trades at prices ranging from $231.96 to $232.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 256 | $230.48 | $59,003.19 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F10 · price: This transaction was executed in multiple trades at prices ranging from $230.295 to $231.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,226 | $229.60 | $281,494.38 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $229.29 to $230.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,144 | $228.93 | $261,890.89 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,177 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F8 · price: This transaction was executed in multiple trades at prices ranging from $228.28 to $229.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 874 | $227.83 | $199,122.55 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,321 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F7 · price: This transaction was executed in multiple trades at prices ranging from $227.28 to $228.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 688 | $226.39 | $155,759.07 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,195 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F6 · price: This transaction was executed in multiple trades at prices ranging from $226.03 to $226.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 246 | $224.74 | $55,285.28 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,883 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $224.61 to $224.745. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,130 | $224.09 | $253,224.75 |
DisclosureSEC source: 0001415889-23-004678 · form4-03102023_050301.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,129 F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $223.61 to $224.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.